CMRX - Chimerix, Inc. Growth-Adjusted Payback Ratio

Chimerix, Inc. (CMRX) is overcoming stringent FDA oversight and high R&D costs by leveraging its oncology patents. Risks are being mitigated through government contracts and the development of antiviral agents. The PEG ratio reflects the valuation dynamics relative to earnings, where the current metric is 0.00. Stability is ensured by a substantial cash reserve to fund prolonged clinical trials.

CMRX Chimerix Inc Price/Earnings to Growth Ratio (07/04/2022 - 04/26/2025)

Metric breakdowns and analytics for Chimerix, Inc. (CMRX)

- current price and projected stock value:

Price Chart Chimerix Inc.|CMRX - Consensus Target

- market capitalization statistics:

Market Value Chimerix, Inc|CMRX - Total Company Value

- book capitalization indicators:

Net Asset Value per Share Chimerix|CMRX - Company Book Value|Capitalization to Book Value Ratio chimerix.com|CMRX - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

CMRX - Net Income|Expected Net Profit Chimerix, Inc.|CMRX - Price to Earnings Ratio|Future Price to Earnings Multiple Chimerix Inc|CMRX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Chimerix, Inc|CMRX - Operating profit EBITDA|Earnings per share for the trailing year Chimerix|CMRX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months chimerix.com|CMRX - Earnings per share growth in current year|Expected earnings per share trend next year Chimerix, Inc.

Fundamental company analysis:Chimerix Inc. CMRX

Demand for Chimerix, Inc. (CMRX) smallpox treatments amid geopolitical tensions is facing logistical barriers, making the PEG ratio dynamics a key analytical tool. This metric compares the P/E ratio with earnings growth rates, identifying an undervalued asset when the value is below one; thus, an investor can filter out market noise and identify the potential for a sharp surge in share prices.

Competitors of Chimerix, Inc.